5-Amino-1MQ the science.

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small, membrane-permeable molecule — not a peptide — that selectively inhibits NNMT. NNMT sits at a busy metabolic crossroads: it consumes both nicotinamide (a precursor the cell uses to make NAD+, the central currency of cellular energy) and S-adenosyl-methionine (SAM, the cell’s main methyl donor). When NNMT activity runs high — a state researchers have observed in obesity, metabolic dysfunction, and aging — it can draw down those pools.

The research rationale is straightforward: if inhibiting NNMT helps preserve NAD+ and SAM, investigators can study how that shift affects fat-cell metabolism, energy expenditure, and tissue maintenance. 5-Amino-1MQ has become a commonly used tool compound for asking those questions in the laboratory.

Most 5-Amino-1MQ research is organized around three connected ideas:

• NAD+ availability — by sparing nicotinamide, NNMT inhibition is studied for how it affects the cell’s NAD+ supply, which powers energy metabolism.
• Methylation balance — sparing SAM is examined in the context of the cell’s methylation reactions and how they interact with metabolism.
• Adipocyte energetics — fat-cell models are used to study lipid synthesis and storage when NNMT is inhibited.

Published 5-Amino-1MQ research is preclinical — carried out in cultured cells and laboratory mice. Two peer-reviewed studies are the most frequently cited:

• Diet-induced obesity models (2018). In mice fed a high-fat diet, researchers reported that selective, membrane-permeable NNMT inhibitors were associated with reduced body weight and adipose (fat) tissue, with the effect attributed to changes in lipid metabolism rather than to reduced food intake.
• Aged-muscle regeneration models (2019). A follow-up study reported that an NNMT inhibitor reactivated senescent (dormant) muscle stem cells and improved the regenerative capacity of aged skeletal muscle in mice.

Across these reports the compound was described as well tolerated in animals at the doses studied. These are observations in cells and animals — they are not evidence of safety, efficacy, or benefit in humans.

The evidence base for 5-Amino-1MQ is entirely preclinical. As of this writing there are no published human clinical trials, and no human safety, dosing, or efficacy has been established. Findings in mice and cell cultures frequently do not translate directly to people. 5-Amino-1MQ is supplied strictly as a research material for in-vitro and laboratory investigation.